New England Journal of Medicine· 2020Q1· Clinical trial
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- 5,074citations
- Q1SCImago
- 2020year
Short summary
Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for worsening heart failure by 25% in patients with heart failure and reduced ejection fraction, regardless of diabetes status.
AI-generated from the title and abstract; the full text is not read.
Key points
- Empagliflozin reduced cardiovascular death or heart failure hospitalization by 25% (hazard ratio 0.75).
- The benefit was consistent across patients with and without diabetes.
- Empagliflozin slowed the decline in kidney function.
- Genital tract infections were more common with empagliflozin.
AI-generated from the title and abstract; the full text is not read.
Abstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS: In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS: of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin. CONCLUSIONS: Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Reduced ClinicalTrials.gov number, NCT03057977.).
The authors' abstract, as published at the source. New England Journal of Medicine, 2020 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine